Is NAMS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Obicetrapib approval path, with revenue (ttm) at ~$22.6M. The bear case rests on the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. Analysts covering it are spread from $36.75 to $60.07, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $36.75, +31.5% from the $27.95 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Obicetrapib approval path. Obicetrapib has posted positive pivotal Phase 3 data (LDL-C reductions of roughly 33% as monotherapy and about 49% combined with ezetimibe in reported studies), which underpins regulatory filings in the US and Europe. The most optimistic analyst target on NAMS is $60.07, +114.9% from the $27.95 price. That figure is only reachable if this thesis works close to its best case.

The company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles. The most pessimistic published target is $36.75, +31.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

NewAmsterdam Pharma Company N.V.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Obicetrapib approval path) stalling in the reported numbers rather than in the narrative, the risk above (the company is pre-commercial with negligible revenue, so the valuation depends on obicetrapib being approved and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It is a late-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease and inherited high-cholesterol conditions. It is pre-commercial, meaning it does not yet sell an approved drug at scale.

Obicetrapib is an oral, once-daily, low-dose CETP inhibitor designed to lower LDL cholesterol, developed alone or as a fixed-dose combination with ezetimibe. In reported Phase 3 trials it lowered LDL-C by roughly 33% as monotherapy and about 49% in combination with ezetimibe.

No. As of the Q1 2026 report (May 2026) the company had only about $3.0 million in quarterly revenue and posted a net loss of roughly $48.4 million. Like most clinical-stage biopharma, it spends heavily on trials while awaiting approval.